

AHCL/ SE/5/2025-26

May 15, 2025

The National Stock Exchange of India Limited "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051 ISIN: INE098F01031 Symbol: AMRUTANJAN	BSE Limited Department of Corporate Services 1 st Floor, P.J. Towers, Dalal Street, Mumbai 400 001 ISIN: INE098F01031 Scrip Code: 590006
--	--

Dear Sir / Madam,

Sub: Outcome of the Board Meeting

In terms of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), we wish to inform that the Board of Directors of the Company at its meeting held today **May 15, 2025** had inter-alia:

- (i) Approved the Audited Financial Results for the quarter and year ended March 31, 2025, as recommended by the Audit Committee at its meeting held today (May 15, 2025) The same along with the Independent Auditor's Report issued by M/s. B S R & Co. LLP, Statutory Auditors of the Company is enclosed.
- (ii) Recommended Final Dividend of Rs. 2.60 per equity share on 2,89,10,630 shares of Re. 1/- each fully paid up for the financial year 2024-25. The Final dividend if approved at the Annual General Meeting will be paid to eligible shareholders within 30 days of AGM.
- (iii) Taken note of the retirement of Mr. M Srinivasan from the post of Company Secretary and Compliance Officer of the Company with effect from close of business hours on May 31, 2025. Please find enclosed Annexure in compliance with Circular Number SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13th, 2023.
- (iv) Approved the appointment of Mr. Gagan Preet Singh as Company Secretary and Compliance Officer of the Company with effect from June 1, 2025. Please find enclosed Annexure in compliance with Circular Number SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13th, 2023.

The Board Meeting commenced at 12:00 P.M and concluded at 4:10 P.M. Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For **Amrutanjan Health Care Limited**

(S Sambhu Prasad)
Chairman and Managing Director

Encl:

1. Audited Standalone Financials Results for the quarter and year ended March 31,2025
2. Independent Auditor's Report for the quarter and year ended March 31, 2025
3. Declaration of Unmodified Opinion.
4. Annexure I as per circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123
5. Annexure II as per circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123

Amrutanjan Health Care Limited

103, (Old No. 42-45), Luz Church Road,
Mylapore, Chennai - 600 004
Tamil Nadu, India.
Tel :+91-44 - 2499 4465
+91-44 - 2466 9000
Fax :+91-44 - 2499 4585

E-mail : customercare@amrutanjan.com
Web Site : www.amrutanjan.com
Toll Free No. : 1 - 800 - 425 - 4545
CIN - L24231TN1936PLC000017

AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Statement of Audited Financial Results for the quarter and year ended 31 March 2025

(Amount in INR in Lakhs)

	Particulars	Quarter ended			Year ended	
		31 March 2025 (Audited - refer note 7)	31 December 2024 (Unaudited)	31 March 2024 (Audited - refer note 7)	31 March 2025 (Audited)	31 March 2024 (Audited)
I	Revenue from operations	13,541.36	12,275.15	12,706.22	45,181.63	42,123.05
II	Other income	481.93	436.03	495.06	1,767.87	1,634.83
III	Total income (I + II)	14,023.29	12,711.18	13,201.28	46,949.50	43,757.88
IV	Expenses					
	(a) Cost of materials consumed	3,494.97	2,597.92	2,895.89	10,059.69	10,336.27
	(b) Purchase of stock-in-trade	3,093.08	3,045.56	3,105.14	12,317.94	10,630.94
	(c) Changes in inventories of finished goods and stock-in-trade	311.33	(63.56)	372.03	(56.90)	215.47
	(d) Employee benefits expense	1,601.73	1,470.27	1,246.39	5,910.27	4,769.36
	(e) Finance cost	4.33	5.59	4.89	21.92	15.67
	(f) Depreciation and amortisation expense	162.22	166.39	153.40	652.61	605.69
	(g) Other expenses					
	- Advertisement and selling expenditure	1,587.73	1,656.16	1,520.17	5,611.04	5,242.28
	- Others	1,682.33	1,233.93	1,942.92	5,519.53	5,747.60
	Total expenses (IV)	11,937.72	10,112.26	11,240.83	40,036.10	37,563.28
V	Profit before tax (III - IV)	2,085.57	2,598.92	1,960.45	6,913.40	6,194.60
VI	Tax expenses	567.79	674.35	594.55	1,829.93	1,697.34
VII	Profit after tax (V - VI)	1,517.78	1,924.57	1,365.90	5,083.47	4,497.26
VIII	Other comprehensive income / (loss)					
	Items that will not be reclassified subsequently to profit or loss					
	Re-measurement gain/(loss) on defined benefit plans, net of taxes	(5.46)	(56.57)	21.57	(105.87)	20.11
	Income tax relating to items that will not be reclassified to profit or loss	1.38	14.24	(4.69)	26.65	(5.06)
	Other comprehensive income/ (loss) for the period / year, net of taxes	(4.08)	(42.33)	16.88	(79.22)	15.05
IX	Total comprehensive income for the period / year (VII + VIII)	1,513.70	1,882.24	1,382.78	5,004.25	4,512.31
	Equity share capital (Face value INR 1/- each, fully paid up)	289.11	289.11	289.11	289.11	289.11
	Other equity				32,372.35	28,559.72
	Earnings per equity share					
	Basic earnings per share (INR)	5.25	6.66	4.72	17.58	15.50
	Diluted earnings per share (INR)	5.25	6.66	4.72	17.58	15.50
		(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)
	<i>See accompanying notes to financial results</i>					

[Handwritten Signature]



AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Note 1: Statement of assets and liabilities

(Amount in INR in Lakhs)

S. No.	Particulars	As at	As at
		31 March 2025	31 March 2024
		Audited	Audited
A	ASSETS		
1	Non-current assets		
	(a) Property, plant and equipment	4,584.52	4,554.78
	(b) Right-of-use assets	188.28	165.13
	(c) Capital work in progress	1,619.78	234.45
	(d) Intangible assets	167.81	232.82
	(e) Intangible assets under development	5.00	5.00
	(f) Financial assets		
	Investments	4.51	4.31
	Other financial assets	4,165.29	1,173.74
	(g) Deferred tax assets (net)	311.17	317.19
	(h) Other tax assets (net)	260.07	260.07
	(i) Other non-current assets	1,765.37	171.39
	Total non-current assets	13,071.80	7,118.88
2	Current assets		
	(a) Inventories	2,725.98	2,890.47
	(b) Financial assets		
	(i) Investments	-	0.05
	(ii) Trade receivables	5,582.18	4,788.94
	(iii) Cash and cash equivalents	1,015.52	371.20
	(iv) Bank balances other than (iii) above	7,300.10	2,289.54
	(v) Other financial assets	11,617.07	18,470.67
	(c) Other current assets	826.15	757.32
	Total current assets	29,067.00	29,568.19
	Total assets (1+2)	42,138.80	36,687.07
B	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity share capital	289.11	289.11
	(b) Other equity	32,372.35	28,559.72
	Total equity	32,661.46	28,848.83
2	Liabilities		
	Non-current liabilities		
	(a) Financial liabilities		
	Lease liabilities	167.63	139.68
	Other financial liabilities	21.50	16.60
	(b) Provisions	829.89	690.11
	Total non-current liabilities	1,019.02	846.39
3	Current liabilities		
	(a) Financial liabilities		
	Lease liabilities	40.18	33.15
	Trade payables		
	total outstanding dues of micro enterprises and small enterprises	193.97	296.72
	total outstanding dues of creditors other than micro enterprises and small enterprises	6,710.30	5,289.54
	Other financial liabilities	168.44	167.03
	(b) Other current liabilities	944.57	840.34
	(c) Provisions	233.65	202.87
	(d) Current tax liabilities (net)	167.21	162.20
	Total current liabilities	8,458.32	6,991.85
	Total liabilities (2+3)	9,477.34	7,838.24
	Total equity and liabilities (1+2+3)	42,138.80	36,687.07

[Handwritten Signature]



Note 2: Statement of Cash flows for the year ended 31 March 2025

Particulars	(Amount in INR in Lakhs)	
	For the year ended 31 March 2025	For the year ended 31 March 2024
	Audited	Audited
Cash flow from operating activities		
Profit before tax	6,913.40	6,194.60
Adjustments for:		
Depreciation and amortisation expense	652.61	605.69
Profit on sale of property, plant and equipment	-	(15.71)
Property plant and equipment written off	-	11.10
Equity-settled share-based payment transactions	114.50	21.50
Loss allowance on trade receivables	25.97	207.05
Bad debts written off	0.42	2.85
Change in fair value of financial assets at FVTPL	(0.20)	12.64
Interest income on cash and cash equivalents and other bank balances	(1,446.57)	(1,258.04)
Interest income on corporate debt securities and loans at amortised cost	(158.15)	(186.15)
Interest income on debt instruments	(0.02)	(36.30)
Excess provision written back, net	(143.69)	(111.44)
Gain on modification of lease	-	(2.30)
Finance costs	21.92	14.08
Operating profit before working capital / other changes	5,980.19	5,459.57
Working capital adjustments:		
(Increase) in trade receivables	(819.63)	(1,696.81)
(Increase) in other assets	(83.78)	(234.07)
(Increase) in other financial assets	(2.35)	(2.47)
Decrease / (increase) in inventories	164.49	(7.96)
Increase / (decrease) in other financial liabilities	12.65	(33.47)
Increase / (decrease) in provisions	64.69	(53.57)
Increase in trade payables	1,461.70	954.09
Increase in other liabilities	104.21	55.46
	901.98	(1,018.80)
Cash generated from operating activities	6,882.17	4,440.77
Less: Income tax paid (net)	(1,792.25)	(1,649.71)
Net cash generated from operating activities (a)	5,089.92	2,791.06
Cash flows from investing activities		
Purchase or construction of property, plant and equipment, intangible assets, capital work-in progress, intangible assets under development, movement in capital advances and payable towards purchase of property, plant and equipment	(3,555.29)	(671.77)
Proceeds from sale of Property, plant and equipment	-	25.86
Investment/ (Redemption) in bank deposits and financial institutions	(1,146.16)	650.38
Interest received on deposits with banks and financial institutions, net	1,604.74	1,336.27
Proceeds from redemption of investments	0.05	500.00
Interest received on debt instruments	0.02	75.76
Net cash (used in) / generated from investing activities (b)	(3,096.64)	1,916.50
Cash flow from financing activities		
Dividend paid	(1,326.65)	(1,338.63)
Sale of shares by employee stock option trust	23.78	117.89
Buy-back of equity shares	-	(2,880.00)
Tax on buy-back of equity shares	-	(670.18)
Payment of lease liabilities	(46.09)	(55.72)
Net cash used in financing activities (c)	(1,348.96)	(4,826.64)
Net Increase / (decrease) in cash and cash equivalents (a) + (b) + (c)	644.32	(119.08)
Cash and cash equivalents at the beginning of the year	371.20	490.28
Effect of exchange rate fluctuations on cash held	-	-
Cash and cash equivalents at the end of the year	1,015.52	371.20
Components of cash and cash equivalents		
Cash on hand	3.70	4.45
Bank balances	1,011.82	366.75
Cash and cash equivalents as per Statement of assets and liabilities	1,015.52	371.20

Note: The above cash flow statement has been prepared under the "indirect method" as set out in the Ind AS 7 on statement of Cash Flows specified under section 133 of the Companies Act, 2013



AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

- Notes:**
3. The above financial results for the quarter and year ended 31 March 2025 in respect of **Amrutanjan Health Care Limited** ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 15 May 2025. The statutory auditors have audited the above results and issued an unmodified opinion.
4. These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
5. The Company does not have any subsidiary/associate/joint venture company(ies) and hence there is no requirement to prepare Consolidated Financial Results.
6. During the financial year 2020-2021, Amrutanjan's Board of Directors had approved the Amrutanjan Health Care Limited Employee stock option scheme ('Scheme 2020') for the grant of stock options to the employees of the Company. The Compensation Committee administers the plan through a trust established specifically for this purpose, called **Amrutanjan Health Care Limited ESOP trust** ('ESOP trust'). The assets and liabilities of the trust is accounted for as assets and liabilities of the Company on the basis that the trust is exclusively set up for the purpose of administering the ESOP plan of the Company. Further, based on the recommendation of the Compensation Committee, the Board of Directors of the Company has approved further grants under the scheme mentioned above, at its meeting held on 23 May 2024.
7. The figures for the quarters ended 31 March 2025 and 31 March 2024 are the balancing figures between audited figures in respect of the full financial years and published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which were subjected to limited review.
8. Interim dividend note of INR.1/- per share, aggregating to INR.289.11 lakhs has been paid during the quarter ended 31 March 2025.
9. The financial results of the Company for the Quarter/Year ended 31 March 2025 have been filed with the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) and are available in Company's website www.amrutanjan.com
10. **Segment reporting in the financial results:** Based on the 'management approach' as defined in Ind AS 108 'Operating Segments', the Chief Operating Decision Maker evaluates the Company's performance as OTC Products, Women's Hygiene, Beverages and Other segments (represents Pain Management Centre). With effect from 1 April 2024, 'OTC Products' segment has been split into 'OTC Products' and 'Women's Hygiene'. Comparative information has been presented accordingly.

Particulars		(Amount in INR in Lakhs)				
		Quarter ended			Year ended	
		31 March 2025 (Audited - refer note 7)	31 December 2024 (Unaudited)	31 March 2024 (Audited - refer note 7)	31 March 2025 (Audited)	31 March 2024 (Audited)
1 Segment revenue						
a OTC Products	8,278.34	8,793.34	7,810.54	29,002.99	27,513.44	
b Women's Hygiene	3,445.55	2,992.59	3,026.66	12,396.25	10,525.88	
c Beverages	1,766.97	441.67	1,866.53	3,643.01	3,998.11	
d Others	50.50	47.55	2.49	139.38	85.62	
Total	13,541.36	12,275.15	12,706.22	45,181.63	42,123.05	
2 Segment results						
a OTC Products	2,026.01	2,396.20	1,929.56	6,557.17	6,171.60	
b Women's Hygiene	(177.23)	(47.14)	(352.99)	(391.05)	(1,077.25)	
c Beverages	34.40	(28.26)	167.41	(243.56)	101.56	
d Others	(22.72)	(16.47)	(17.57)	(81.43)	(93.60)	
Total	1,860.46	2,304.33	1,726.41	5,841.13	5,102.31	
Less: Finance cost	4.33	5.59	4.89	21.92	15.67	
Add: Interest income net of other unallocable expenditure	229.44	300.18	238.93	1,094.19	1,107.96	
Total profit before tax	2,085.57	2,598.92	1,960.45	6,913.40	6,194.60	
3 Segment assets						
a OTC Products	6,800.73	6,843.98	7,126.75	6,800.73	7,126.75	
b Women's Hygiene	5,209.00	3,664.16	1,902.00	5,209.00	1,902.00	
c Beverages	3,503.26	2,391.71	3,524.46	3,503.26	3,524.46	
d Others	122.13	115.08	92.80	122.13	92.80	
e Unallocated assets	26,503.68	26,277.31	24,041.06	26,503.68	24,041.06	
Total	42,138.80	39,292.24	36,687.07	42,138.80	36,687.07	
4 Segment liabilities						
a OTC Products	5,539.80	5,453.53	4,615.57	5,539.80	4,615.57	
b Women's Hygiene	1,646.36	1,215.97	1,245.85	1,646.36	1,245.85	
c Beverages	1,359.50	508.28	1,198.39	1,359.50	1,198.39	
d Others	42.67	40.01	1.15	42.67	1.15	
e Unallocated liabilities	889.01	665.32	777.28	889.01	777.28	
Total	9,477.34	7,883.11	7,838.24	9,477.34	7,838.24	
Total capital employed in the Company	32,661.46	31,409.13	28,848.83	32,661.46	28,848.83	

For Amrutanjan Health Care Limited

Date: 15 May 2025
Place: Chennai




S Sambhu Prasad
Chairman & Managing Director
DIN: 00015729

Independent Auditor's Report

To the Board of Directors of Amrutanjan Health Care Limited

Report on the audit of the Annual Financial Results

Opinion

We have audited the accompanying annual financial results of **Amrutanjan Health Care Limited** (hereinafter referred to as the "Company") for the year ended 31 March 2025, attached herewith, (in which are included financial statements of an **Amrutanjan Health Care Limited ESOP Trust** ("ESOP trust")) being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive loss and other financial information for the year ended 31 March 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the annual financial results.

Management's and Board of Directors' / Board of Trustees Responsibilities for the Annual Financial Results

These annual financial results have been prepared on the basis of the annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these annual financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the Company / Board of trustees of the ESOP trust are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company / ESOP trust and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively

Registered Office:

Independent Auditor's Report (Continued)

Amrutanjan Health Care Limited

for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the annual financial results, the respective Management and the Board of Directors / Board of trustees are responsible for assessing Company's / ESOP trust's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors / Board of trustees either intends to liquidate the company / ESOP trust or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors / Board of trustees are responsible for overseeing the financial reporting process of the Company / ESOP trust.

Auditor's Responsibilities for the Audit of the Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the annual financial results, including the disclosures, and whether the annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Independent Auditor's Report (Continued)
Amrutanjan Health Care Limited


Other Matter

- a. The annual financial results include the results for the quarter ended 31 March 2025 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022



R Kalyana Sundara Rajan

Partner

Membership No.: 221822

UDIN:25221822BMMKDK1161

Chennai

15 May 2025



ANNEXURE

DECLARATION

Pursuant to Regulation 33 (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

It is hereby declared and confirmed that the Auditor's Report of Annual Financial Results of the Company is with unmodified opinion.

This declaration is furnished in reference to the provision to clause (d) of Sub-Regulation (3) of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your records.

Thanking you,

Yours faithfully,

For **Amrutanjan Health Care Limited**

N Swaminathan
Chief Financial Officer
Date : 15.05.2025





**INTEGRATED FILING (FINANCIAL) FOR THE QUARTER AND YEAR
ENDED 31ST MARCH, 2025**

Sl. No.	Particulars	Remarks
1	Financial Results: Audited Financial Results for the quarter and year ended 31st March, 2025 (Standalone)	Enclosed
2	Statement on Deviation or Variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.,	Not Applicable
3	Format for disclosing outstanding default on loans and debt securities	Not Applicable
4	Format for disclosure of related party transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)	Enclosed
5	Statement on impact of audit qualifications (for audit report with modified opinion) submitted along - with annual audited financial results (standalone and consolidated separately) (applicable only for annual filing i.e., 4th quarter)	Not Applicable
6	Declaration that the Auditor's Report of Annual Financial Results of the Company is with unmodified opinion	Enclosed



ANNEXURE I

Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/CIR/2023/123 dated July 13, 2023

Retirement of Company Secretary and Compliance Officer

Name	Mr. M Srinivasan
Reason for Change (appointment, re- appointment, resignation, removal, death or otherwise)	Retirement of Mr. M Srinivasan as Company Secretary and Compliance Officer.
Date of Retirement	May 31, 2025
Brief Profile (in case of appointment)	Not Applicable
Disclosure of Relationship between Directors (in case of appointment of a director).	Not Applicable



ANNEXURE II

Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/CIR/2023/123 dated July 13, 2023

Appointment of Company Secretary and Compliance Officer

Name	Mr. Gagan Preet Singh
Reason for Change (appointment, re- appointment, resignation, removal, death or otherwise)	Appointment of Mr. Gagan Preet Singh as Company Secretary and Compliance Officer with effect from June 1, 2025.
Date of Appointment	June 1, 2025
Brief Profile (in case of appointment)	<p>Mr. Gagan Preet Singh is a fellow member of the Institute of Company Secretaries of India and holds a law degree from the Faculty of Law, University of Delhi.</p> <p>He is a seasoned Governance and Legal Professional with over two decades of experience spanning diverse sectors, including automotive and FMCG. Before joining Amrutanjan, he held key roles with leading Indian listed companies like Bajaj Hindustan Group, Allsec Technologies, handling their secretarial and legal portfolios.</p> <p>With a proven track record in managing complex projects, he has been instrumental in driving strategic legal initiatives, ensuring regulatory compliance, and strengthening governance frameworks. As a key member of the Leadership Team, he has worked in close collaboration with the Board of Directors.</p> <p>His expertise spans corporate governance, development and implementation of the best-corporate policies & codes of conduct, and leadership in key areas such as contract management, litigation management and corporate secretarial.</p>
Disclosure of Relationship between Directors (in case of appointment of a director).	Not Related to any other directors of Amrutanjan Health Care Limited